Reference:
PROJECT1
Abstract:
Objective: confirmed the reversibility of the syndrome Rett, a possible therapeutic approach could result by pharmacological modulation of molecular pathways regulated by MeCP2. In this project we will remove MeCP2 from cerebral cortex and hippocampus, areas in which they reside most of the cognitive and affective, to determine the “MeCP2 target genes” responsible for specific symptoms or molecular defects. The second experimental phase involves the analysis of the data obtained for the development of one or more pharmacological interventions, the results of which, compared with data molecular and behavioral previously obtained, we allow to evaluate their effectiveness.
PROJECT DETAILS
beginning: 2010.
end: 2012.
Country of research: Italy
Counry of funding source: Italy
Funding organization: Pro Rett Ricera
Financing: PRIVATE FUNDERS – 80 000 €